LY 510929

Drug Profile

LY 510929

Alternative Names: LY 929

Latest Information Update: 23 Mar 2009

Price : $50

At a glance

  • Originator Eli Lilly; Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Phenylpropionates; Small molecules; Thiophenes
  • Mechanism of Action Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia; Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 23 Mar 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
  • 23 Mar 2009 Discontinued - Phase-I for Metabolic disorders in USA (unspecified route)
  • 23 Mar 2009 Discontinued - Phase-I for Hyperlipidaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top